Purpose To describe the global effort targeting the major causes of mortality in terms of "open" early phase clinical trials with drugs and biologicals. Methods Sixteen of the 20 leading causes of death were chosen; 9 of these were also amongst the top 10 causes of death in low-income countries. Studies were identified from the ClinicalTrials.gov database and included phase 1 and/or 2 "interventional" "open" trials, i.e. those recruiting or about to start recruitment. Trials were considered in terms of sponsorship [industry, universities and other organisations (UNO), and US federal agencies (NIH included)], genders and age groups included, and whether they were conducted with drugs and/or biologicals. The search was performed in March 2010. Results A total of 2,298 (824 phase 1; 1,474 phase 2) trials were retrieved. Of these, 67% were on trachea, bronchus, and lung cancers (25%); diabetes mellitus (15%); colon and rectum cancers (14%); and HIV/AIDS (12%). In contrast, only 4% were trials on diarrhoeal disease, nephrosis and nephritis, liver cirrhosis, and prematurity and low birth weight. UNO were the first source of funding. Fifty-two percent of phase 1 non-cancer trials were on healthy volunteers. Twenty-nine percent of all trials were co-funded. There were 4.6 times as many drug trials as those with biologicals. Only 7% were conducted with a combination of drugs and biologicals, the majority (78%) on cancers. Discrimination in terms of gender or age group was not observed. Conclusions Four of the 16 diseases considered represented 2/3 of early phase trials. Cancers were a top priority for all sponsors. Increasing attention should be given to conditions with current and projected global high mortality rates that had few "open" early phase trials.
became effective in 2005, requiring investigators to register information about their trials in an accepted clinical trials registry before starting patient enrolment [1] . Soon after, under World Health Organization (WHO) leadership, a multidisciplinary team agreed on the minimum data set about design, conduct and administration of a study to be disclosed. Contrary to the initial ICMJE proposal, it was decided that all trials-including phase 1-must be registered before study start [2] [3] [4] . Data showed that the ICMJE policy dramatically impacted the number of trials registered on the largest registry, ClinicalTrials.gov (CTG) [5] . Thus, 1 month after the policy went into effect, the number of registered trials jumped from >13,000 to close to 23,000 [6] . In March 2010, close to 88,000 studies were registered in CTG. The increasing registration of trials in CTG before the initiation of subject recruitment [5] and the publication of the WHO comprehensive report about the leading causes of death [7] made it possible to analyse the global effort in terms of early phase trials devoted to investigating new medicines or new approaches with drugs or biologicals to combat the major causes of mortality on a worldwide basis.
Methods
This analysis was conducted using ClinicalTrials.gov registered studies as of March 24, 2010 . A careful assessment of the impact of the search fields was carried out to provide the optimal inclusion of data to be reviewed. To fulfil the study objective, the "open" (i.e. "recruiting",
"not yet recruiting") rather than the "closed" (i.e. "active, but not recruiting") descriptor was preferred, and although studies that were "active, but not recruiting" anymore may be lost, it would avoid the inclusion of studies that were "terminated" or "completed" some years back. So, the fields chosen were "study type: interventional", "recruitment: open"; "study results: all"; "conditions"; "interventions: drugs and/or biologicals"; "gender"; "age group"; "phase: 1 and/or 2"; "funded: university/organization (UNO), industry (INY) and National Institutes of Health and other U.S. federal agency" (FED), merged together (Appendix). In addition, "healthy volunteers" was used as a specific search term. Although CTG has a validation system in place [9] , it relies ultimately on the accuracy of the data introduced by thousands of scientists, and this can be a source of inconsistencies and errors in the CTG fields. A review of inconsistencies was conducted when reviewing the data retrieved from CTG.
Sixteen of the 20 leading causes of death for the year 2004, accounting for 58% of all worldwide mortality, were included in the analysis [7] . Since WHO and CTG may name diseases or conditions differently, among CTG's "conditions" the one that could best match each of the WHO's causes of death was chosen, using ICD10 as guidance [8] (Table 1) . However, with ischaemic heart disease, hypertensive heart disease and cerebrovascular disease, more than one "condition" was chosen in order to capture the majority of studies (Table 1) . On the other hand, WHO's diarrhoeal diseases is more restrictive that CTG's diarrhoea; hence, the search was done excluding traveller's diarrhoea and diarrhoea associated with antibiotics, chemotherapy, radiation, irritable bowel disease, IBS and cancer.
Among the 20 conditions, 4 were not included in this analysis: 3 are not suitable for experimental clinical research ("road traffic accidents", "self-inflicted injuries" and "birth asphyxia and birth trauma"), whereas the fourth one ("neonatal infections") had a complex definitionaccording to the WHO description, the category also includes 'other non-infectious causes arising in the perinatal period, that are responsible for 20% of deaths in this category' [7] -making it impossible to match it with CTG conditions.
Results
In 2004, 71 "open", "interventional" phase 1 studies with drugs and/or biologicals were registered at CTG, 14 of them associated with the 16 conditions considered here; these figures were 150 and 17 for phase 2 trials respectively. In 2010, the total number of "open", "interventional" phase 1 trials and those related to the 16 conditions increased to 4,145 and 824, respectively; these figures were 6,552 and 1,474 for phase 2 trials, respectively (Table 2 ). U.S. centres were involved in 56% of all phase 1 and/or 2 trials for the diseases considered.
Specific data on the number of phase 1 and 2 trials, with regards to the 16 conditions, sponsorship, gender and age groups accepted for inclusion are shown in Tables 2, 3 and 4 . Sixty-seven percent of all phase 1 and/or 2 trials were on trachea, bronchus and lung cancers (25%, 574/2,298), diabetes mellitus (15%, 346/2,298), colon and rectum cancers (14%, 333/2,298) and HIV/AIDS (12%, 283/2,298) ( Table 2) . Only 4% addressed diarrhoeal disease, nephrosis and nephritis, liver cirrhosis, and prematurity and low birth weight. Malaria was the only condition with more phase 1 than phase 2 trials. The number of trials with drugs was 4.6-fold higher than those with biologicals. Seven percent (161/ 2,298) were conducted with a combination of drugs and biologicals, the majority (78%, 126/161) on cancers ( Table 2) . Fifty-two percent of phase 1 non-cancer trials were conducted on healthy volunteers; 36% of phase 1 trials were labelled as phase 1 and 2 trials ( Table 2) . UNO were the first source of funding (60%, 1,378/2,298), and among these 46% (627/1,378) were co-funded. Twenty-nine percent (674/ 2,298) of all studies were co-funded (Table 3) .
Twelve percent (270/2,298) of phase 1 and/or 2 trials accepted subjects up to 17 years old. Respiratory tract infections, diabetes and HIV/AIDS accounted for 54% in both phase 1 (52/97) and 2 (93/173) trials accepting minors (Table 4) . Seniors were included in trials for almost all diseases except in prematurity and low birth weight trials. Females and males were accepted for inclusion in both phase 1 and 2 trials in a balanced manner in all conditions (Table 4) . The most striking finding observed was not the fact that cancers (mainly trachea, bronchus and lung cancers and colon and rectum neoplasms) received the most interest from sponsors, but the high percentage of effort devoted to them. Forty-five percent of trials were on cancers; only HIV/AIDS and diabetes mellitus were single conditions of significant interest for FED and INY respectively. Hence, the global effort in early cancer development trials is really remarkable. There were many medicines (and new combination regimens) in early phase trials that hopefully will help future patients in high-and middle-income countries in which both trachea, bronchus and lung cancers and stomach cancers are predicted to be among the 10 leading causes of mortality in 2030 [10] . Of note is also the number of biologicals in early clinical development, expanding the approaches to the treatment of cancer patients. To this end, modern technology (e.g. cancer genomics and proteomics, circulating tumour cells) and the use of validated biomarkers are key to increasing the success of cancer treatment [11] .
On the other hand, there were a number of diseases of almost no interest to public and private sponsors. These included conditions not only prevalent in developing countries (e.g. diarrhoea, prematurity and low birth weight) but also in developed societies (e.g. COPD). It is clear that prevention and treatment of these conditions should mainly rely on individual behavioural (e.g. smoking, diet, alcohol intake, physical activity) and community (e.g. water supply, sanitation) changes, and this would explain, to some extent, the scarce number of trials initiated with drugs and biologicals.
Data suggest that overall participation of women and men in trials supporting the marketing authorisation of new medicines in Europe [12] and the U.S. [13] is comparable. However, significant under-representation of women in early phase trials has been also observed. Fleish et al. found an overall proportion of only 37% of female participants in phase 1 and 2 trials results published in 2001 in three major clinical pharmacology journals [14] . Furthermore, more recent data showed that among 352 "conditions" abbreviations, see Table 1 a Because some studies were funded by more than one funding source, the sum of the studies funded by each source is greater than the total number of studies Adults 18-65 years old, seniors ≥66 years old For "conditions" abbreviations, see Table 1 a Because many studies included more than one age group or gender, the sum of the studies by each age group and gender is greater than the total number of studies phase 1 trials of 30 new molecular entities submitted to the U.S. Food and Drug Administration (FDA) in 2006-2007 for non-sex-specific indications, only 31% of participants were women and that 34% of trials had only male volunteers [15] . This analysis shows that there was not a gender bias in the selection criteria of early phase clinical trials. This being required, is not enough to ensure women are appropriately represented: female participants should be actively invited to participate in these early phase trials. In this respect, the data of Pinnow et al. [15] are encouraging: the number of trials that enrolled women and the number of women participating in phase 1 trials has increased since 2001, although women are still under-represented. Finally, it should be highlighted that Pinnow's analysis shows no gender discrimination in both healthy volunteers and patient trials, the first step to prevent what was previously observed [14] , i.e. that there is a higher proportion of women participating in patient trials than in healthy volunteer ones.
The present study shows that elderly people were not excluded from most of the early development trials. In a 2005 editorial, McMurdo et al. [16] shared their concerns regarding the evidence that older people were excluded from clinical trials. This is more relevant for cancer trials than for the other conditions considered in this study, since volunteers in oncology trials have to be patients from the very beginning of clinical research. Trials submitted to the FDA supporting new cancer therapies [17] showed that the elderly were under-represented for all cancer treatments except breast cancer hormonal therapies, despite the fact that seniors are willing to consider participation in cancer trials [18] . This analysis shows that elderly people could participate in 99% of phase 1 and/or 2 cancer trials. However, what really matters is to actually have enough seniors participating in these trials, thereby enabling better designed phase 3 studies for this patient population.
Minors were accepted in only 12% of all phase 1 and/or 2 trials on drugs and biologicals. This figure might seem low considering the recent legislative changes in both the U.S. [19] and the European Union [20] aiming to increase the development of medicines for use in the paediatric population. However, a number of factors could help to explain this, including that many of the conditions considered here are not prevalent in this population (e.g. ischaemic heart disease, cerebrovascular disease), and that it is prudent to gather enough data in adults before trying new medicines in children-although this should not postpone the conduct of appropriate studies. Trials should pursue the acquisition of data, but at the same time should not subject children to unnecessary risks. The fact that 40% of phase 1 and/or 2 trials on malaria were on or accepted minors is encouraging. In any case, many reports are being published pointing out specific challenges and needs (and approaches to address them) regarding the diseases considered in this analysis in the paediatric population [21] [22] [23] [24] [25] .
Determining how to label a given trial, as phase 1 or as phase 2, can be tricky. When a scientist is filling in the CTG fields of a trial, the rather simple (and short) definitions provided in CTG can be used as guidance (Appendix). However, scientists could follow more detailed definitions, such as the ones provided by the ICH Tripartite Harmonised Guideline [26] , in which phase 1 trials are mostly human pharmacology studies, whereas phase 2 are typically therapeutic exploratory trials. Excluding cancer trials, this analysis shows that among phase 1 studies there were very similar numbers of healthy volunteer and patient trials-furthermore, some studies had both healthy and patient subjects-and that a remarkable number were labelled as phase 1 and 2 trials. It seems that, in practice, the border between the two phases is getting blurred to some extent.
Strengths and limitations
This analysis has the limitation of being based on the trials registered in only one database (CTG), although this is the largest (the number of registered studies in CTG is more than 10 times as many as the second one, ISRCTN [27] ) and the most international one available. Currently 38% of all "open" "interventional" phase 1 and/or 2 trials with drugs and/or biologicals have no U.S. participation; this number is 44% when considering only the 16 leading causes of mortality. A second limitation is the difficulty assessing how the "conditions" in CTG correspond exactly to the WHO's "leading causes of death". In most instances, there was no problem in making this match. However, in diseases such as ischaemic heart disease and cerebrovascular disease, some trials could have been lost in the search performed in CTG. This should not, however, have impacted the overall results obtained, since to fulfil the aim of the analysis it was not necessary to include all the studies, but the majority.
Finally, another limitation could come from inconsistencies and errors that scientists might have made when filling in the CTG fields. Inconsistencies were found in some cases, for example a phase 1 trial (NCT00492102) and a phase 2 trial (NCT00238056) on prematurity and low birth weight were found that accepted seniors. A few trials labelled as phase 1 would be more appropriately labelled as phase 2. For example, study NCT00783107, a randomised, double-blind, placebo-controlled trial that aimed to "evaluate the safety and effectiveness of aerosol cyclosporine" in treating COPD patients, and study NCT00476918, a randomised, double-blind trial comparing high vs. low triamcinolone acetonide dose to assess the "visual acuity, number of treatments and duration of efficacy" for the treatment of diabetic macular edema, seemed more like phase 2 studies than phase 1. Although 136 trials on healthy volunteers were labelled as phase 1, 122 other healthy volunteer trials were not labelled as such. Among these, there were errors such as three nephrosis or nephritis trials (NCT00298506, NCT00302536 and NCT00302523) that were labelled as admitting healthy volunteers as participants but were in fact opened only for patients; these three studies were conducted at the same university, two of them by the same study director. Also, occasionally there were errors in the keywords that could prevent a correct search. Thus, for instance, NCT00955344 is a study aiming to assess if a behavioural intervention increases physician rates of colorectal cancer recommendation that nevertheless appeared in this search that was focussed only on trials with drugs and/or biologicals. Again, while acknowledging that this has happened (and will happen in the future), the impact should be limited since this analysis included both phase 1 and 2 trials as well as the healthy volunteer studies with no labelled phase. The scenario would have been different if only phase 1 trials were included in the study, due to the confusion that could arise between phase 1 and or 2 in labelling some studies.
It is worth mentioning that the analysis was based on the leading causes of death for the year 2004. These causes are expected to continue to be an important source of mortality and morbidity in the two decades to come. Thus, 11 of the diseases considered are among the 15 leading causes of mortality projected for 2030 [10] , and 5 of them are among the top 10 projected major causes of disability adjusted life years [10] . The high burden of disability caused by mental diseases should be kept in mind, although no mental diseases were among the 20 leading causes of death [7] . In this respect, unipolar depressive disorders are projected to be the second worldwide cause of disability adjusted life years in 2030, and to be among the three top leading causes of disability in high-, middle-and low-income countries [10] .
The number of registered healthy volunteer studies seems rather low and was clustered in three conditions (diabetes, HIV/AIDS and respiratory tract infections) accounting for 71% of all trials. It is difficult to assess the extent of "open" healthy volunteer studies that were not registered on CTG. Bioequivalence trials (aimed at gathering data for marketing authorisation for generic products) are usually not registered, most likely because sponsors are not interested in publishing the results in peer-reviewed journals. Even taking this into consideration, 256 studies in healthy volunteers seems surprisingly low, with conditions such as hypertensive heart disease and cerebrovascular disease represented in only 1 and 4 "open" trials respectively. Maybe the WHO [4] request to register phase 1 trials has not yet been widely followed by researchers when dealing with healthy volunteer trials.
Conclusions
It is of concern to observe than 2/3 of the currently "open" early phase trials addressed only 4 of the 16 leading causes of death considered in this analysis. Furthermore, 45% of all phase 1 and/or 2 were on cancers, a top priority for all sponsors. While acknowledging that neoplasms will continue to be a leading cause of mortality in the years to come, and that individual behavioural (e.g. smoking, diet, physical activity) and community (e.g. sanitation) interventions have to play a major role in the prevention and management of the vast majority of these 16 diseases, it seems rather disappointing to observe that early clinical research with new medicines, new combination regimens and new approaches with drugs and/or biologicals was fairly scarce in conditions afflicting millions of people globally. In this regard, it was surprising the relatively few "open" trials conducted on three of the five major projected causes of death in 2030 in high-, middle-and low-income countries [10] , i.e. ischaemic heart disease, cerebrovascular disease and COPD. At the same time, it was encouraging to observe the increasing effort against malaria, although there are yet many issues to be addressed [28] .
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